相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
Aleksandr S. Martianov et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Kristen K. Ciombor et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
Sebastian Stintzing et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Role of Genetic Ancestry in 1,002 Brazilian Colorectal Cancer Patients From Barretos Cancer Hospital
Ronilson Oliveira Duraes et al.
FRONTIERS IN ONCOLOGY (2020)
Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations
Jesus Arturo Hernandez-Sandoval et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2020)
Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age
Allan A. Lima Pereira et al.
CLINICAL COLORECTAL CANCER (2020)
Occurrence of the potent mutagens 2-nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles
Aldenor G. Santos et al.
SCIENTIFIC REPORTS (2019)
Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients
Gustavo Noriz Berardinelli et al.
Oncotarget (2018)
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Jonathan M. Loree et al.
CLINICAL CANCER RESEARCH (2018)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar et al.
JAMA ONCOLOGY (2017)
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer A Systematic Review and Meta-analysis
Fausto Petrelli et al.
JAMA ONCOLOGY (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
A. Rowland et al.
BRITISH JOURNAL OF CANCER (2015)
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Frank A. Sinicrope et al.
CLINICAL CANCER RESEARCH (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
S. Y. Brule et al.
EUROPEAN JOURNAL OF CANCER (2015)
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites
Yan Zhang et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2015)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance
Markus Morkel et al.
ONCOTARGET (2015)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
E. Missiaglia et al.
ANNALS OF ONCOLOGY (2014)
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer-Results from NCIC CTG/AGITG CO.17
Christos S. Karapetis et al.
CLINICAL CANCER RESEARCH (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy
L. S. Yamane et al.
ONCOLOGY REPORTS (2014)
The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Fausto Meriggi et al.
REVIEWS ON RECENT CLINICAL TRIALS (2014)
Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series
M. A. Merok et al.
ANNALS OF ONCOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients
Carla G. Rasuck et al.
MOLECULAR BIOLOGY REPORTS (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study
Robert Lim et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study
Antonio C. Buzaid et al.
CLINICAL COLORECTAL CANCER (2010)
NRAS Mutations Are Rare in Colorectal Cancer
Natsumi Irahara et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy.: A report of the AIO Colorectal Study Group
C. I. Mueller et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2008)
Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
Hansjochen Wilke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
